NI201300106A - Composición farmacéutica antihipertensiva - Google Patents

Composición farmacéutica antihipertensiva

Info

Publication number
NI201300106A
NI201300106A NI201300106A NI201300106A NI201300106A NI 201300106 A NI201300106 A NI 201300106A NI 201300106 A NI201300106 A NI 201300106A NI 201300106 A NI201300106 A NI 201300106A NI 201300106 A NI201300106 A NI 201300106A
Authority
NI
Nicaragua
Prior art keywords
pharmaceutical composition
antihypertensive pharmaceutical
solvate
hydrate
pharmaceutically acceptable
Prior art date
Application number
NI201300106A
Other languages
English (en)
Inventor
Ho Kim Seung
Han Kim Ji
Sang Yu Kyung
Jin Jang In
Goo Shin Sang
Hyun Yoon Seo
Youn Cho Joo
Eun Kim Tae
Jeong Yi So
Heui Paik Soo
Ha Chi Yong
Han Lee Joo
Wan Nam Kyung
Hak Kim Je
Original Assignee
Boryung Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47006840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201300106(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boryung Pharm filed Critical Boryung Pharm
Publication of NI201300106A publication Critical patent/NI201300106A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La presente invención proporciona una composición farmacéutica antihipertensiva que contiene Fimasartan, una sal farmacéuticamente aceptable del mismo, un solvato del mismo o un hidrato del mismo como un bloqueador del receptor de angiotensina II; y Amlodipina, un isómero de la misma, una sal farmacéuticamente aceptable de la misma, un solvato de la misma o un hidrato de la misma como un bloqueador del canal de calcio.
NI201300106A 2011-04-12 2013-10-11 Composición farmacéutica antihipertensiva NI201300106A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20110033856 2011-04-12

Publications (1)

Publication Number Publication Date
NI201300106A true NI201300106A (es) 2014-05-05

Family

ID=47006840

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201300106A NI201300106A (es) 2011-04-12 2013-10-11 Composición farmacéutica antihipertensiva

Country Status (20)

Country Link
US (1) US8765776B2 (es)
JP (1) JP5782178B2 (es)
AU (1) AU2011365756B2 (es)
BR (1) BR112013025222B8 (es)
CA (1) CA2832758C (es)
CL (1) CL2013002905A1 (es)
CO (1) CO6821940A2 (es)
CR (1) CR20130526A (es)
EA (1) EA024096B1 (es)
EC (1) ECSP13012962A (es)
GT (1) GT201300241A (es)
MA (1) MA35107B1 (es)
MX (1) MX341450B (es)
MY (1) MY160432A (es)
NI (1) NI201300106A (es)
PE (1) PE20141049A1 (es)
SG (1) SG194162A1 (es)
UA (1) UA110244C2 (es)
WO (1) WO2012141385A1 (es)
ZA (1) ZA201307593B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024096B1 (ru) 2011-04-12 2016-08-31 Борюн Фармасьютикал Ко., Лтд. Противогипертоническая фармацевтическая композиция
KR101490329B1 (ko) * 2012-10-12 2015-02-04 보령제약 주식회사 피마살탄 포타슘염의 일수화물 결정, 그 제조방법, 및 그를 포함하는 약제학적 조성물
KR20140096514A (ko) * 2013-01-28 2014-08-06 보령제약 주식회사 암 예방 또는 치료용 조성물
AU2014230182B2 (en) * 2013-03-14 2016-12-22 Boryung Pharmaceutical Co., Ltd. Pharmaceutical combination drug
KR20150041223A (ko) * 2013-10-04 2015-04-16 보령제약 주식회사 피마살탄을 포함하는 허혈성 뇌질환 예방 또는 치료용 약학적 조성물
CN105395552A (zh) * 2014-09-05 2016-03-16 南京华威医药科技开发有限公司 一种含非马沙坦及其盐的固体制剂
KR101545268B1 (ko) * 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
WO2017091041A1 (ko) * 2015-11-26 2017-06-01 보령제약 주식회사 피마살탄의 신규 염
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
CN112704667A (zh) * 2021-02-24 2021-04-27 施慧达药业集团(吉林)有限公司 含苯磺酸左氨氯地平水合物的组合物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161312C (da) 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
CA1334092C (en) 1986-07-11 1995-01-24 David John Carini Angiotensin ii receptor blocking imidazoles
EP0733366B1 (en) 1988-01-07 1998-04-01 E.I. Du Pont De Nemours And Company Pharmaceutical compositions comprising angiotensin II receptor blocking imidazoles and diuretics
KR100300566B1 (ko) 1994-09-17 2001-11-22 조생현 피리미디논유도체와그의제조방법및용도
KR19990081093A (ko) * 1998-04-25 1999-11-15 조생현 피리미디논 화합물, 이를 함유하는 약제학적 조성물 및 이의제조방법
SK285863B6 (sk) * 1998-07-10 2007-10-04 Novartis Ag Kombinovaná farmaceutická kompozícia obsahujúca AT1-antagonistu valsartan a amlodipín
FR2783422A1 (fr) 1998-09-21 2000-03-24 Sanofi Sa Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire
KR100617953B1 (ko) 2000-03-23 2006-08-30 보령제약 주식회사 피리미디논 화합물 및 이의 염의 제조방법
AU2001292386B2 (en) * 2001-09-21 2006-06-22 Boryung Pharmaceutical Co., Ltd. Method for preparing pyrimidinone compound and pharmaceutically acceptable salts thereof
KR100521980B1 (ko) 2002-10-10 2005-10-17 보령제약 주식회사 피리미디논 화합물 및 이의 염의 삼수화물의 제조 방법
BRPI0612674B8 (pt) * 2005-06-27 2021-05-25 Daiichi Sankyo Co Ltd preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
KR20100048137A (ko) 2008-10-30 2010-05-11 현대약품 주식회사 혈압 강하용 약학 조성물
KR101058284B1 (ko) 2010-01-22 2011-08-22 보령제약 주식회사 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법
EA024096B1 (ru) 2011-04-12 2016-08-31 Борюн Фармасьютикал Ко., Лтд. Противогипертоническая фармацевтическая композиция

Also Published As

Publication number Publication date
CL2013002905A1 (es) 2014-04-11
JP5782178B2 (ja) 2015-09-24
BR112013025222A2 (pt) 2016-12-27
US20120264772A1 (en) 2012-10-18
US8765776B2 (en) 2014-07-01
PE20141049A1 (es) 2014-09-05
MA35107B1 (fr) 2014-05-02
AU2011365756B2 (en) 2015-07-30
CO6821940A2 (es) 2013-12-31
GT201300241A (es) 2015-08-13
CR20130526A (es) 2014-03-11
UA110244C2 (en) 2015-12-10
JP2014510785A (ja) 2014-05-01
EA024096B1 (ru) 2016-08-31
WO2012141385A1 (en) 2012-10-18
MX341450B (es) 2016-08-19
EA201370219A1 (ru) 2014-02-28
CA2832758A1 (en) 2012-10-18
MX2013011879A (es) 2014-03-31
ZA201307593B (en) 2015-04-29
MY160432A (en) 2017-03-15
SG194162A1 (en) 2013-11-29
ECSP13012962A (es) 2013-11-29
BR112013025222B8 (pt) 2020-05-05
CA2832758C (en) 2015-12-15
AU2011365756A1 (en) 2013-10-31
BR112013025222B1 (pt) 2020-03-17

Similar Documents

Publication Publication Date Title
NI201300106A (es) Composición farmacéutica antihipertensiva
MX2019011926A (es) Metodos utiles en la sintesis de analogos de halicondrina b.
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1116645T1 (el) Ενωση-αναστολεας σηματοδοτικου μονοπατιου notch
BR112016007805A2 (pt) receptor de antígeno quimérico
MX2016005297A (es) Inhibidores del receptor del factor de crecimiento de fibroblastos.
CL2011003147A1 (es) Compuestos derivados de n-(1-4-(1h-pirazol-5-il)ftalazina-1-il) piperidina-4-il) benzamida; composicion farmaceutica que los contiene, utiles como antagonista de la trayectoria de hedgehog, en el tratamiento del cancer.
EA201201263A1 (ru) Фармацевтическая композиция, содержащая этексилат дабигатрана
EA201691327A1 (ru) Полиморфные формы (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
MX341825B (es) Compuestos de heteroarilo y usos de los mismos.
TW201144301A (en) Processes for preparing linezolid
EA201590272A1 (ru) Пероральные дозированные формы для модифицированного высвобождения, содержащие руксолитиниб
EA201490761A1 (ru) R(+)-n-формилпропаргиламиноиндан
EA201600442A1 (ru) Мягкая фармацевтическая композиция на водной основе, содержащая тапентадол
BR112014025041B8 (pt) Composição farmacêutica
MX354818B (es) Moduladores del receptor x del higado.
EA201201202A1 (ru) Пероральная фармацевтическая композиция, содержащая этексилат дабигатрана
EA201101118A1 (ru) Фармацевтические композиции, включающие производные 2-оксо-1-пирролидина
CL2018000290A1 (es) Antagonistas del receptor de cgrp
EA201692043A1 (ru) Лекарственная форма иммунодепрессанта
GEP201706739B (en) Compositions comprising vortioxetine and donepezil
CU24163B1 (es) Composición farmacéutica oftalmológica tópica que contiene regorafenib
EA201390603A1 (ru) Многослойная фармацевтическая композиция, содержащая телмисартан и амлодипин
BR112013018781A2 (pt) composto derivado de piridona, e, composição farmacêutica
WO2013119607A3 (en) Modified release formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione